Tobira Therapeutics (TBRA) Posts Q2 Loss of $0.71/Share; Ended Qtr with $41M in Cash

Tobira Therapeutics (NASDAQ: TBRA) reported Q2 EPS of ($0.71), $0.08 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $1.06 million versus the consensus estimate of $50 thousand.

s of June 30, 2016, Tobira had cash, cash equivalents, and restricted cash of $41.0 million.

“We are excited about the results of the CENTAUR trial, which we believe is the first study to prospectively meet an endpoint recommended for Phase 3 studies to support marketing authorization, namely ‘an improvement in fibrosis by at least one stage without worsening of NASH.’ This is an important milestone as fibrosis is a key predictor of mortality and liver-related events. We are confident about our path forward, and we look forward to discussing the Phase 3 study with regulators and presenting the CENTAUR data at a medical meeting later this year,” said Laurent Fischer, M.D., chief executive officer of Tobira. “On the strength of the fibrosis data, we are also advancing our NASH program with a Phase 1 trial of cenicriviroc in combination with evogliptin, which is targeted at the metabolic abnormalities implicated in NASH and complements CVC.”

For earnings history and earnings-related data on Tobira Therapeutics (TBRA) click here.

You May Also Be Interested In

• Google (GOOGL) Makes Structural Changes to AI Teams to Quicken Progress: CEO
• Genuine Parts (GPC) Tops Q1 EPS by 5c, Offers Guidance
• Intelligent Bio Solutions (INBS) Reports Prelim Q3 Results